围手术期应用氯胺酮对术后抑郁的疗效与安全性:随机对照研究Meta分析
该Meta分析纳入15项随机对照研究、氯胺酮组1697例与对照组1462例,评估围手术期静脉给予氯胺酮对术后抑郁的影响。结果显示氯胺酮可降低术后第1、3、7天及长期抑郁评分,并降低术后第1天疼痛VAS评分,但增加恶心呕吐、头痛、幻觉和头晕风险。
要点
- 围手术期氯胺酮可降低术后第1、3、7天及长期抑郁评分。
- 氯胺酮降低术后第1天疼痛VAS评分,第3、7天及长期无显著差异。
- 氯胺酮增加恶心呕吐、头痛、幻觉和头晕风险。
核心结论
- 围手术期应用氯胺酮可降低术后抑郁和疼痛评分,但增加不良事件风险。
研究设计与样本
- Meta分析纳入15项比较氯胺酮与安慰剂的随机对照试验,氯胺酮组1697例,对照组1462例。
主要发现
- 术后第1天抑郁评分SMD为-0.97(95%CI -1.27至-0.66,P<0.001,I2=72%)。
- 术后第3天抑郁评分SMD为-0.65(95%CI -1.12至-0.17,P<0.001,I2=94%)。
- 术后第7天抑郁评分SMD为-0.30(95%CI -0.45至-0.14,P<0.001,I2=0%)。
- 长期抑郁评分SMD为-0.25(95%CI -0.38至-0.11,P<0.001,I2=59%)。
- 术后第1天疼痛VAS评分SMD为-0.93(95%CI -1.58至-0.29,P=0.005,I2=97%),第3、7天及长期无显著差异。
关键数值与推荐
- 恶心呕吐RR为1.40(95%CI 1.12至1.75,P=0.003,I2=30%)。
- 头痛RR为2.47(95%CI 1.41至4.32,P=0.002,I2=19%)。
- 幻觉RR为15.35(95%CI 6.24至37.34,P<0.001,I2=89%)。
- 头晕RR为3.48(95%CI 2.68至4.50,P<0.001,I2=89%)。
临床怎么用
- 围手术期氯胺酮可用于减轻术后抑郁症状,但需监测恶心呕吐、头痛、幻觉和头晕等不良事件。
局限性
- 术后第1天和第3天抑郁评分分析异质性较高(I2分别为72%和94%)。
- 疼痛VAS评分术后第1天分析异质性高(I2=97%)。
- 幻觉和头晕分析异质性高(I2均为89%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ketamine, a commonly used general anesthetic, can produce rapid and sustained antidepressant effect. However, the efficacy and safety of the perioperative application of ketamine on postoperative depression remains uncertain. We performed a meta-analysis to determine the effect of perioperative intravenous administration of ketamine on postoperative depression. Randomized controlled trials comparing ketamine with placebo in patients were included. Primary outcome was postoperative depression scores. Secondary outcomes included postoperative visual analog scale (VAS) scores for pain and adverse effects associated with ketamine. Fifteen studies with 1697 patients receiving ketamine and 1462 controls were enrolled. Compared with the controls, the ketamine group showed a reduction in postoperative depression scores, by a standardized mean difference (SMD) of -0.97, 95% confidence interval [CI, -1.27, -0.66], P < 0.001, I2 = 72% on postoperative day (POD) 1; SMD-0.65, 95% CI [-1.12, -0.17], P < 0.001, I2 = 94% on POD 3; SMD-0.30, 95% CI [-0.45, -0.14], P < 0.001, I2 = 0% on POD 7; and SMD-0.25, 95% CI [-0.38, -0.11], P < 0.001, I2 = 59% over the long term. Ketamine reduced VAS pain scores on POD 1 (SMD-0.93, 95% CI [-1.58, -0.29], P = 0.005, I2 = 97%), but no significant difference was found between the two groups on PODs 3 and 7 or over the long term. However, ketamine administration distinctly increased the risk of adverse effects, including nausea and vomiting (risk ratio [RR] 1.40, 95% CI [1.12, 1.75], P = 0.003, I2 = 30%), headache (RR 2.47, 95% CI [1.41, 4.32], P = 0.002, I2 = 19%), hallucination (RR 15.35, 95% CI [6.24, 37.34], P < 0.001, I2 = 89%), and dizziness (RR 3.48, 95% CI [2.68, 4.50], P < 0.001, I2 = 89%) compared with the controls. In conclusion, perioperative application of ketamine reduces postoperative depression and pain scores with increased risk of adverse effects.
引用
- Guo J, Qiu D, Gu HW, et al. Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies. Mol Psychiatry. 2023. PMID: 36670198. doi:10.1038/s41380-023-01945-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。